PARP inhibitors Prostate Cancer Genomics Study IDs PARP Inhibitors as Potentially Beneficial to Black Men Some genes were more frequently mutated in prostate cancers from Black men, but the researchers said that social inequities also lead to poorer health outcomes. Personalis to Provide Immunogenomic Profiling for University of New Mexico Ovarian Cancer Study The company will test samples from women treated with an investigational combination of AstraZeneca's PARP inhibitor olaparib and immunotherapy tremelimumab. Harvard Team Advancing Algorithmic Signature to Improve PARP Inhibitor Patient Selection Premium The group published results showing its method can faithfully recapitulate genome-wide measures of DNA repair deficiency using much smaller sequencing panels. FDA Approves Myriad Genetics' BRACAnalysis CDx With Lynparza in Earlier Ovarian Cancer Setting The test is now approved as a CDx for advanced ovarian cancer patients considering Lynparza as a first-line maintenance treatment. FDA Approves Myriad Genetics BRCA CDx With Pfizer's Metastatic Breast Cancer Drug The test is approved to gauge germline BRCA mutations in advanced breast cancer patients who may benefit from treatment with Pfizer's PARP inhibitor Talzenna. Oct 10, 2018 Myriad Upgraded to Overweight by Piper Jaffray; Signs Lab Service Deal with Pfizer Sep 28, 2018 BRCA1 Methylation Level May Predict Which Ovarian Cancer Patients Respond to PARP Inhibitors Jul 16, 2018 PARP Inhibitors May Benefit Patients With Rare Hereditary Cancer Syndromes May 31, 2018 PanDrugs System Aims to Advance Precision Cancer Care by Matching Treatments to Mutations Premium May 11, 2018 PARP Inhibitor Resistance Gene Identified Using CRISPR Screen Dec 8, 2017 Pfizer PARP Inhibitor Delays Progression Over Chemotherapy in BRCA-Mutated Advanced Breast Cancer Premium Jul 11, 2017 After Securing CE-IVD for Debut Hereditary Cancer Dx, Korea's NGeneBio Readies NGS Tests for Launch Premium Mar 27, 2017 FDA Approves Myriad Genetics' BRACAnalysis as Complementary Dx for New PARP Inhibitor Feb 1, 2017 Clovis, Strata Partner to Identify Prostate Cancer Best Responders to PARP Inhibitor Dec 20, 2016 Foundation Medicine's Regulatory Win for NGS CDx Sets Precedent; Adoption Challenge Remains Premium Dec 19, 2016 Foundation BRCA CDx is First NGS Companion Test to Get FDA Nod Nov 2, 2016 Myriad Moving Ahead With PMA Filing for MyChoice HRD as Companion Test for Niraparib Premium Jul 6, 2016 Ovarian Cancer Study Provides Support for Myriad's HRD Test as CDx for Tesaro's Niraparib Premium Jun 6, 2016 AstraZeneca Outlines Precision Medicine Strategy for DNA Damage Response Portfolio Premium Mar 1, 2016 Multiplicom Receives CE-IVD Mark for Ovarian Cancer CDx Test Feb 23, 2016 AbbVie to Use Myriad CDx to Support PARP Inhibitor Development Jan 18, 2016 Tumor Cell, Mouse Studies Suggest c-Met Expression as Predictor of PARP Inhibitor Resistance Oct 30, 2015 Mutational Signature Points to Possibility of Targeted Treatment for Some Stomach Cancers Jan 12, 2015 JP Morgan Healthcare Conference, Day One: Genomic Health, Myriad Genetics Nov 24, 2014 In Ongoing Phase II Trial, Clovis Still Refining 'BRCAness' Signature for PARP Inhibitor Rucaparib Premium Load More Breaking News Enzo Biochem, CLX Health Partner to Support COVID-19 Testing for International Travel Type 1 Diabetes GWAS, Fine-Mapping Leads to New Genetic Loci, Potential Drug Targets LSU Health Sciences Center Wins $2.4M to Lead SARS-CoV-2 Variant Sequencing Program NanoString Technologies, Parker Institute for Cancer Immunotherapy Partner on Cell Therapy Project BGI Americas Collaborating With Champions Oncology on Proteomic Cancer Research Personal Genome Diagnostics Inks Cancer Genomic Profiling Deal with Duke University Health System The Scan Missed Early Cases A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports. Limited Journal Editor Diversity A survey finds low diversity among scientific and medical journal editors, according to The Scientist. How Much of a Threat? Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned. PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.